Stock Scorecard



Stock Summary for Jaguar Health Inc (JAGX) - $3.94 as of 5/15/2026 1:43:44 AM EST

Total Score

6 out of 30

Safety Score

18 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for JAGX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for JAGX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for JAGX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for JAGX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for JAGX (18 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for JAGX

Jaguar Health: May 26 Q1 webcast, CEO at May 28 Lytham event 5/20/2026 12:40:00 PM
Jaguar Health Exchanges Series Q Preferred to Cut $22.7 Million in Royalty Obligations 5/19/2026 9:39:00 PM
Jaguar Health (JAGX) Initiates Key Pediatric Clinical Trial Phase 5/19/2026 2:10:00 PM
Jaguar Health’s crofelemer trial advances for rare pediatric disease 5/19/2026 1:10:00 PM
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer 5/19/2026 1:10:00 PM
Ultrarare pediatric disease: first patient enters crofelemer trial extension 5/19/2026 1:10:00 PM
Jaguar Health Delays Quarterly Filing Briefly 5/18/2026 8:10:00 PM
Jaguar Health (NASDAQ: JAGX) delays Q1 2026 10-Q, cites subsequent events 5/18/2026 7:10:00 PM
Jaguar Health, Inc. - Common Stock (NQ: JAGX) 5/17/2026 8:40:00 AM
Jaguar Health stock (US47010C1053): volatile biotech name in focus after latest financing moves 5/17/2026 5:55:00 AM

Financial Details for JAGX

Company Overview

Ticker JAGX
Company Name Jaguar Health Inc
Country USA
Description Jaguar Health, Inc., a commercial-stage pharmaceutical company, focuses on developing prescription drugs for people and animals with gastrointestinal upset, specifically chronic debilitating diarrhea. The company is headquartered in San Francisco, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date 5/21/2026

Stock Price History

Last Day Price 3.94
Price 4 Years Ago 8,079.55
Last Day Price Updated 5/15/2026 1:43:44 AM EST
Last Day Volume 66,303
Average Daily Volume 462,168
52-Week High 186.55
52-Week Low 2.53
Last Price to 52 Week Low 55.73%

Valuation Measures

Trailing PE N/A
Industry PE 22.92
Sector PE 63.24
5-Year Average PE -8,785.19
Free Cash Flow Ratio 1.52
Industry Free Cash Flow Ratio 18.79
Sector Free Cash Flow Ratio 28.36
Current Ratio Most Recent Quarter 0.50
Total Cash Per Share 2.60
Book Value Per Share Most Recent Quarter -99.20
Price to Book Ratio 1.62
Industry Price to Book Ratio 12.52
Sector Price to Book Ratio 22.11
Price to Sales Ratio Twelve Trailing Months 0.16
Industry Price to Sales Ratio Twelve Trailing Months 9.25
Sector Price to Sales Ratio Twelve Trailing Months 4.72
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 513,940
Market Capitalization 2,024,924
Institutional Ownership 1.43%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -39.18%
Reported EPS 12 Trailing Months -803.95
Reported EPS Past Year -35.31
Reported EPS Prior Year -130.96
Net Income Twelve Trailing Months -66,031,000
Net Income Past Year -53,575,000
Net Income Prior Year -38,492,000
Quarterly Revenue Growth YOY -7.80%
5-Year Revenue Growth 4.17%
Operating Margin Twelve Trailing Months -632.00%

Balance Sheet

Total Cash Most Recent Quarter 968,000
Total Cash Past Year 968,000
Total Cash Prior Year 8,002,000
Net Cash Position Most Recent Quarter -6,680,000
Net Cash Position Past Year -14,115,000
Long Term Debt Past Year 15,083,000
Long Term Debt Prior Year 23,503,000
Total Debt Most Recent Quarter 7,648,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -17,289,000
Total Stockholder Equity Prior Year 7,285,000
Total Stockholder Equity Most Recent Quarter -17,289,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -21,995,000
Free Cash Flow Per Share Twelve Trailing Months -42.80
Free Cash Flow Past Year 5,773,000
Free Cash Flow Prior Year -29,615,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.76
MACD Signal -2.89
20-Day Bollinger Lower Band -1,313.82
20-Day Bollinger Middle Band 16.66
20-Day Bollinger Upper Band 1,347.13
Beta 0.03
RSI 25.55
50-Day SMA 3,891.48
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 5/20/2026 1:44:50 AM EST